San Diego Business Journal


Recent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...

Suneva Medical Raises $35.4 Million in Capital

San Diego-based Suneva Medical Inc., a developer of facial skin products, announced the closing of a $15 million equity investment by Almirall Inc., an affiliate of Almirall S.A., a global pharmaceutical company primarily focused within the therapeutic area of medical dermatology.

Tease photo

Lyford Readies for Her New Leadership Role at West Health

RESEARCH: As CEO, She’ll Look to Unify Efforts To Support Senior Population

If you’re looking to find a charismatic executive with a New York City tongue, Vermont’s dairy country probably wouldn’t be your starting point.

Tease photo

Injecting Capital

MEDICINE: Health Care Systems Are Creating VC Arms Often to Invest in Promising Innovations for Providing Care

Hospital systems dealing with high-tech glitches and chaotic workflow brought on by health care reform are launching venture capital funds to fuel the solutions they need.

Senomyx Inc. Reports Q2 Net Loss of $2.7 Million

Senomyx Inc., a biotechnology company that makes flavor enhancers, reported a net loss of $2.7 million for the second quarter of 2015, up slightly from the $2.6 million net loss from the same period last year.

President of Salk Institute to Retire at End of Year

BIOTECH: Brody Made Scientific and Financial Improvements

William Brody will retire at the end of the year as president of the Salk Institute for Biological Studies in La Jolla, opening up a third major leadership position in San Diego’s science community.

Tease photo

Brain Injury Diagnosis Crucial to Treatments

MEDICINE: Co. Exploring Biomarkers to Detect Damage

Banyan Biomarkers gained yardage recently in its bid to help the National Football League and other sports organizations diagnose traumatic brain injuries.

Ignyta Gets FDA Clearance for New Drug Application

San Diego-based Ignyta Inc., a precision oncology company, reported that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application milestone for the company’s tumor-fighting compound known as RXDX-107.

NuVasive Reports Q2 Net Income of $10.3 Million

NuVasive Inc. on Tuesday reported second-quarter net income of $10.3 million, after reporting a loss in the same period a year earlier.

UCSD, La Jolla Institute for Allergy and Immunology Sign Agreement

The La Jolla Institute for Allergy and Immunology announced Monday an official affiliation agreement with the University of California, San Diego Health System.

Salk Institute's President, William Brody, Retiring

William Brody will retire at the end of the year as president of the Salk Institute for Biological Studies in La Jolla, opening up a third major leadership position in San Diego’s science community.

VetStem and Animal Hospital Announce Partnership

Poway-based VetStem Biopharma, a veterinary regenerative medicine company, and VCA Emergency Animal Hospital & Referral Center recently announced an educational and clinical partnership in support of local area vets.

Quidel Corp. Reports Q2 Revenue is Up 11 Percent

Quidel Corp. reported that revenue was up 11 percent for the second quarter of 2015, according to a recent earnings statement.

Biotechs Insulate Region as IPO Market Cools

BIOTECH: Surge in Private Financing Allows Some Cos. to Put Off IPO

The once white-hot market for initial public offerings in the U.S. has cooled in recent months as private companies stay private longer or opt to be taken out by larger rivals. But the local biotechnology scene may be insulating San Diego from the trend.

Lpath Inc. Initiating Phase 1 Clinical Trial of Key Antibody

San Diego-based Lpath Inc. announced that it’s initiating a Phase 1 clinical trial to study Lpathomab within the next two months.

Illumina Records Q2 Revenue of $539 Million

Shares of Illumina Inc. have fallen nearly 10 percent this week after the gene-sequencing company announced second-quarter revenue missed analysts’ expectations on Tuesday.